Amy G. Feldman

Amy G. Feldman

Auto-generated profile, based on publicly available information

Amy G. Feldman

Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute University of Colorado School of Medicine and Children's Hospital Colorado Aurora Colorado USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in The Journal of Pediatrics
Verified
Journal Article
Closed access
AFAmy G. Feldman
Amy G. Feldman
JPJulie A. Parsons
Julie A. Parsons
CDCullen M. Dutmer
Cullen M. Dutmer
AVAravindhan Veerapandiyan
Aravindhan Veerapandiyan
EHEinar Hafberg
Einar Hafberg
CMCara L. Mack
Cara L. Mack

2 October 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AFAmy G. Feldman
Amy G. Feldman
BBBrenda L. Beaty
Brenda L. Beaty
JFJose A. Ferrolino
Jose A. Ferrolino
GMGabriela Maron
Gabriela Maron
HWHillary K. Weidner
Hillary K. Weidner
LDLara A. Danziger-Isakov
Lara A. Danziger-Isakov
Importance: Live vaccines (measles-mumps-rubella [MMR] and varicella-zoster virus [VZV]) have not been recommended after solid organ transplant due to concern for inciting vaccine strain infection in an immunocompromised host. However, the rates of measles, mumps, and varicella are rising nationally and internationally, leaving susceptible immunocompromised children at risk for life-threating conditions.Objective: To determine the safety and immunogenicity of live vaccines in pediatric liver and kidney transplant recipients.Design, Setting, and Participants: This cohort study included select pediatric liver and kidney transplant recipients who had not completed their primary MMR and VZV vaccine series and/or who displayed nonprotective serum antibody levels at enrollment between January 1, 2002, and February 28, 2023. Eligibility for live vaccine was determined by individual US pediatric solid organ transplant center protocols.Exposures: Exposure was defined as receipt of a posttransplant live vaccine. Transplant recipients received 1 to 3 doses of MMR vaccine and/or 1 to 3 doses of VZV vaccine.Main Outcome and Measure: Safety data were collected following each vaccination, and antibody levels were obtained at 0 to 3 months and 1 year following vaccination. Comparisons were performed using Mann-Whitney U test, and factors associated with development of postvaccination protective antibodies were explored using univariate analysis.Results: The cohort included 281 children (270 [96%] liver, 9 [3%] kidney, 2 [1%] liver-kidney recipients) from 18 centers. The median time from transplant to enrollment was 6.3 years (IQR, 3.4-11.1 years). The median age at first posttransplant vaccine was 8.9 years (IQR, 4.7-13.8 years). A total of 202 of 275 (73%) children were receiving low-level monotherapy immunosuppression at the time of vaccination. The majority of children developed protective antibodies following vaccination (107 of 149 [72%] varicella, 130 of 152 [86%] measles, 100 of 120 [83%] mumps, and 124 of 125 [99%] rubella). One year post vaccination, the majority of children who initially mounted protective antibodies maintained this protection (34 of 44 [77%] varicella, 45 of 49 [92%] measles, 35 of 42 [83%] mumps, 51 of 54 [94%] rubella). Five children developed clinical varicella, all of which resolved within 1 week. There were no cases of measles or rubella and no episodes of graft rejection within 1 month of vaccination. There was no association between antibody response and immunosuppression level at the time of vaccination.Conclusions and Relevance: The findings suggest that live vaccinations may be safe and immunogenic after solid organ transplant in select pediatric recipients and can offer protection against circulating measles, mumps, and varicella.

13 February 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAmy G Feldman
Amy G Feldman
SOSean T O’lEary
Sean T O’lEary
LDLara Danziger-Isakov
Lara Danziger-Isakov
Nationally, immunization delivery has decreased significantly during the coronavirus disease 2019 (COVID-19) pandemic. Internationally, >60 national vaccine programs have been disrupted or suspended. As a result of these immunization declines, the global community is at risk for a resurgence in vaccine-preventable infections including measles, pertussis, and polio—all highly contagious diseases that result in significant morbidity and mortality in children. Measles outbreaks have already occurred in many countries that suspended their vaccination programs. Outbreaks in the United States are likely to occur when social distancing stops and children return to school. Healthcare providers have acted quickly to institute multiple risk mitigation strategies to restore vaccine administration. However, childhood immunization rates remain below pre–COVID-19 levels. Partnerships between healthcare providers, community leaders, and local, state, regional, and national public health departments are needed to reassure families that vaccine delivery during COVID-19 is safe and to identify and catch up those children who are underimmunized.

12 November 2019 in JAMA
Verified
Journal Article
Open access
PDF file
AFAmy G. Feldman
Amy G. Feldman
SSShikha S. Sundaram
Shikha S. Sundaram
BBBrenda L. Beaty
Brenda L. Beaty
RTRichard Torres
Richard Torres
DCDonna J. Curtis
Donna J. Curtis
AKAllison Kempe
Allison Kempe
Vaccine-preventable infections are a serious complication following transplant. In a multicenter retrospective cohort study of 6980 pediatric solid organ transplant recipients between 2004 and 2011, 15.6% were hospitalized with a vaccine-preventable infection in the first 5 years after transplant at a rate of up to 87 times higher than in the general pediatric population.1 Immunizations are a minimally invasive, cost-effective way to reduce the incidence of these infections. We quantified the percentage of patients at Society of Pediatric Liver Transplantation centers who were up to date for their age on immunizations at the time of transplant and determined whether demographic and clinical factors were associated with immunization status at the time of transplant.

1 March 2017 in The Journal of Pediatrics
Verified
Journal Article
Closed access
AFAmy G. Feldman
Amy G. Feldman
RSRonald J. Sokol
Ronald J. Sokol
RHRegina M. Hardison
Regina M. Hardison
EAEstella M. Alonso
Estella M. Alonso
RSRobert H. Squires
Robert H. Squires
MNMichael R. Narkewicz
Michael R. Narkewicz

1 March 2017 in The Journal of Pediatrics
Verified
Journal Article
Closed access
AFAmy G. Feldman
Amy G. Feldman
SSShikha S. Sundaram
Shikha S. Sundaram
BBBrenda L. Beaty
Brenda L. Beaty
AKAllison Kempe
Allison Kempe